"Helio Genomics...presented and discussed recent CLiMB trial data evaluating HelioLiver, a multi-analyte blood test, in patients with hepatocellular carcinoma (HCC), as well as its cell-free DNA (cfDNA) methylation biomarkers for assessing prognosis and treatment response at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting held November 18, 2024 and virtual KOL event held November 25, 2024. Both events featured Helio’s Chief Medical Advisor, Dr. Richard Van Etten, MD, PhD."